Lophos Holdings IncCanadian Securities Exchange:MESC
- LAST PRICE0.0550
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0550
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MESC |
|---|
May 15, 2024
Lophos Pharmaceuticals Corp. Receives Traditional Blessing for Napanee Site in Honor of Indigenous Heritage, from 8:02AM ET on Wednesday May 15, 2024 by Dow Jones
8:02AM ET on Wednesday May 15, 2024 by Dow Jones
May 6, 2024
Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com, from 7:59AM ET on Monday May 06, 2024 by Dow Jones
7:59AM ET on Monday May 06, 2024 by Dow JonesPress Release: Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com, from 7:59AM ET on Monday May 06, 2024 by Dow Jones
7:59AM ET on Monday May 06, 2024 by Dow Jones
May 2, 2024
Lophos Pharmaceuticals Corp. Commences Peyote Research Protocol, from 8:00AM ET on Thursday May 02, 2024 by Dow Jones
8:00AM ET on Thursday May 02, 2024 by Dow Jones
Apr 25, 2024
Lophos Pharmaceuticals Corp. Expands Peyote Cultivation with the Successful Planting of 3,000 Seeds, from 8:00AM ET on Thursday Apr 25, 2024 by Dow Jones
8:00AM ET on Thursday Apr 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lophos Holdings Inc | 4.7M | 0.0x | --- |
WPD Pharmaceuticals Inc | 5.0M | -64.3x | --- |
Marvel Biosciences Corp | 3.6M | -1.4x | --- |
Hemostemix Inc | 3.5M | -1.3x | --- |
Quest Pharmatech Inc | 3.4M | -0.2x | --- |
Bright Minds Biosciences Inc | 6.3M | -0.8x | --- |
Company Information
Lophos Holdings Inc. is a Canada-based company, which is engaged in the cultivation and research of Lophophora williamsii (peyote cactus). The Company is also engaged in the research and development of compounds derived from the peyote cactus. The Company's cultivated peyote cactus will be used by the Company to conduct pre-clinical research and development in Canada either directly through a Controlled Substance Dealers License (CSDL) at its Napanee facility, or indirectly with one or more third-party partners. The Company's CSDL licensing includes the development of intellectual property related to the chemical composition of peyote and the custom formulation of Mescaline and related compounds and the research and development of drug delivery systems for Mescaline and other related molecules. It also operates a Health Canada licensed analytical testing and research and development institution, to conduct pre-clinical research and development through Sigma Analytical Services Inc.
Contact Information
- Headquarters
- 620 - 1111 Melville StreetVANCOUVER, BC, Canada V6E 3V6
- Phone
- 604-401-6656
- Fax
- ---
Executives
- Chief Executive Officer, Director
- Jacqueline Lupo
- Chief Financial Officer
- Remantra Sheopaul
- Director
- Solomon Elimimian
- Director
- Evan Stawnyczy
- Independent Director
- Elyssia Patterson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.7M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 85.9M |
Lophos Holdings Inc does not pay a dividend. | |
Beta | --- |
EPS | --- |
Book Value | $0.02 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
